Inhibition of Hepatitis B Virus Replication by Helper Dependent Adenoviral Vectors Expressing Artificial Anti-HBV Pri-miRs from a Liver-Specific Promoter
Open Access
- 5 June 2014
- journal article
- research article
- Published by Hindawi Limited in BioMed Research International
- Vol. 2014, 1-12
Abstract
Research on applying RNA interference (RNAi) to counter HBV replication has led to identification of potential therapeutic sequences. However, before clinical application liver-specific expression and efficient delivery of these sequences remain an important objective. We recently reported short-term inhibition of HBV replicationin vivoby using helper dependent adenoviral vectors (HD Ads) expressing anti-HBV sequences from a constitutively active cytomegalovirus (CMV) promoter. To develop the use of liver-specific transcription regulatory elements we investigated the utility of the murine transthyretin (MTTR) promoter for expression of anti-HBV primary microRNAs (pri-miRs). HD Ads containing MTTR promoter effected superior expression of anti-HBV pri-miRs in mice compared to HD Ads containing the CMV promoter. MTTR-containing HD Ads resulted in HBV replication knockdown of up to 94% in mice. HD Ads expressing trimeric anti-HBV pri-miRs silenced HBV replication for 5 weeks. We previously showed that the product of the codeliveredlacZgene induces an immune response, and the duration of HBV silencingin vivois likely to be attenuated by this effect. Nevertheless, expression of anti-HBV pri-miRs from MTTR promoter is well suited to countering HBV replication and development of HD Ads through attenuation of their immunostimulatory effects should advance their clinical utility.Keywords
This publication has 44 references indexed in Scilit:
- Targeted DNA Mutagenesis for the Cure of Chronic Viral InfectionsJournal of Virology, 2012
- Sustained miRNA-mediated Knockdown of Mutant AAT With Simultaneous Augmentation of Wild-type AAT Has Minimal Effect on Global Liver miRNA ProfilesMolecular Therapy, 2012
- Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liverJournal of Clinical Investigation, 2010
- Inhibition of hepatitis B virus replication with linear DNA sequences expressing antiviral micro-RNA shuttlesBiochemical and Biophysical Research Communications, 2009
- Efficient silencing of gene expression with modular trimeric Pol II expression cassettes comprising microRNA shuttlesNucleic Acids Research, 2009
- Optimization of linear double-stranded RNA for the production of multiple siRNAs targeting hepatitis C virusRNA, 2009
- Treatment of Chronic Viral Hepatitis in Woodchucks by Prolonged Intrahepatic Expression of Interleukin-12Journal of Virology, 2009
- Expression of shRNA From a Tissue-specific pol II Promoter Is an Effective and Safe RNAi TherapeuticMolecular Therapy, 2008
- Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAiProceedings of the National Academy of Sciences, 2008
- Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathwaysNature, 2006